Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 push

Sobi has bought into Innate Pharma’s vision for lacutamab, handing the French biotech $75 million upfront for the rights to market the anti-KIR3DL2 antibody for an aggressive skin cancer.